Pfizer is working to get approval on a new vaccine that could protect people against Lyme disease.

Pfizer is working to get approval on a new vaccine that could protect people against Lyme disease. WBZ-TV's Mike Sullivan ...

The vaccine demonstrated a reduction in the rate of infections, but fell short of a key statistical requirement.

A Lyme disease vaccine produced by Pfizer and Valneva was deemed 70 percent effective by the companies after they reviewed ...

Pfizer says it's going to seek approval for its Lyme disease vaccine. That's despite the shot failing a late-stage trial.

If approved by regulators, it could become the only Lyme disease vaccine available for people — although it would not be the ...

Pfizer and France's Valneva said on Monday their experimental Lyme disease vaccine showed ‌more than 70% efficacy in a ...

Drugmaker Pfizer and French vaccine company Valneva said their vaccine, called LB6V, worked more than 70% of the time in a ...

The companies said the vaccine was 73% effective in reducing the rate of Lyme disease 28 days after the fourth dose.

Presented by Alliance for Aging Research{beacon} Health Care Health Care PRESENTED BY The Big Story Pfizer’s Lyme disease ...

Despite the study missing its primary endpoint, Pfizer will continue with the regulatory submission of the vaccine.

There hasn't been an approved Lyme disease vaccine for more than 20 years, after GSK pulled its shot due to a lack of demand.